Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer
Aim: Assess factors associated with EGFR TKI initiation among patients with metastatic non-small-cell lung cancer (mNSCLC). Patients & methods: Medicare Part D patients diagnosed with non-squamous mNSCLC and starting an EGFR TKI within 1 year of diagnosis were selected from the Surveillance, Epi...
Main Authors: | Chow, L.Q.M (Author), Kwong, W.J (Author), Marrett, E. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Future Medicine Ltd.
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
by: Ahn, H.K, et al.
Published: (2022) -
Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer
by: Bai, H., et al.
Published: (2022) -
The Root Extract of Peucedanum praeruptorum Dunn Exerts Anticancer Effects in Human Non-Small-Cell Lung Cancer Cells with Different EGFR Mutation Statuses by Suppressing MET Activity
by: Jeong, J.-H, et al.
Published: (2022) -
The Root Extract of Peucedanum praeruptorum Dunn Exerts Anticancer Effects in Human Non-Small-Cell Lung Cancer Cells with Different EGFR Mutation Statuses by Suppressing MET Activity
by: Jeong, J.-H, et al.
Published: (2022) -
EGFR Mutation as a Predictive Factor to Treatment Response of TKI (Tyrosine Kinase Inhibitor) in Non-Small Cell Lung Cancer Stage 4: A Case Report
by: Wulyo Rajabto, et al.
Published: (2021-03-01)